We are live on ! Find out more
BVF Inc

BVF Inc Portfolio holdings

AUM $3.04B Turnover 10.42%
1-Year Est. Return 129.63%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+129.63%
3 Year Est. Return
+531.24%
5 Year Est. Return
+1,335.11%
10 Year Est. Return
+16,856.28%
AUM
$916M
AUM Growth
+$22.5M
Cap. Flow
+$9.33M
Cap. Flow %
1.02%
Top 10 Hldgs %
50.42%
Holding
61
New
8
Increased
22
Reduced
19
Closed
5
Avg Time Held
1.8 years
Top 10 Avg Time Held
1.6 years
Top 20 Avg Time Held
1.6 years

Top Sells

Rank Stock Value
1
ARRY icon
Array Biopharma
ARRY
+$62.5M
2
ARQL
Arqule
ARQL
+$38.5M
3
BPMC icon
Blueprint Medicines
BPMC
+$10.5M
4
ARGX icon
argenx
ARGX
+$10.1M
5
VBIV icon
VBI Vaccines
VBIV
+$8.83M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
MRUS icon
1
DELISTED
Merus
MRUS
$68M 7.42%
4,639,413
+99,500
+2% +$1.41M
2018 Q1
5 quarters
CYTK icon
2
Cytokinetics
CYTK
$7.17B
$58.2M 6.36%
5,176,878
+1,375,061
+36% +$13.3M
2013 Q2
24 quarters
ARRY icon
3
DELISTED
Array Biopharma
ARRY
$55.3M 6.04%
1,193,224
-2,227,338
-65% -$62.5M
2013 Q2
24 quarters
ACIU icon
4
AC Immune
ACIU
$212M
$54.5M 5.95%
9,819,434
+2,363,900
+32% +$12M
2018 Q3
3 quarters
MRTX
5
DELISTED
Mirati Therapeutics
MRTX
$54.3M 5.93%
527,253
+95,553
+22% +$7.44M
2018 Q2
4 quarters
KURA icon
6
Kura Oncology
KURA
$675M
$43.4M 4.74%
2,204,119
-291,037
-12% -$4.83M
2017 Q3
7 quarters
BPMC icon
7
DELISTED
Blueprint Medicines
BPMC
$41.3M 4.51%
437,565
-127,400
-23% -$10.5M
2015 Q2
16 quarters
INFI
8
DELISTED
Infinity Pharmaceuticals
INFI
$31.4M 3.43%
17,426,968
– –
2016 Q2
12 quarters
RCUS icon
9
Arcus Biosciences
RCUS
$2.27B
$28.1M 3.07%
3,535,223
+725,000
+26% +$7.26M
2018 Q1
5 quarters
MTEM icon
10
DELISTED
Molecular Templates
MTEM
$27.2M 2.97%
217,101
-21,508
-9% -$2.34M
2017 Q3
7 quarters
XOMA icon
11
DELISTED
Xoma
XOMA
$26.7M 2.92%
1,796,942
+27,913
+2% +$419K
2016 Q4
10 quarters
CALA
12
DELISTED
Calithera Biosciences
CALA
$26.3M 2.88%
337,524
+186,350
+123% +$21.2M
2018 Q3
3 quarters
REPL icon
13
Replimune Group
REPL
$1.82B
$25.3M 2.76%
1,724,609
+117,792
+7% +$1.7M
2018 Q3
3 quarters
CTMX icon
14
CytomX Therapeutics
CTMX
$447M
$21M 2.3%
1,873,617
+675,617
+56% +$7.08M
2019 Q1
1 quarter
CNCE
15
DELISTED
Concert Pharmaceuticals
CNCE
$19.5M 2.13%
1,628,187
+242,700
+18% +$2.61M
2014 Q3
19 quarters
DRNA
16
DELISTED
Dicerna Pharmaceuticals
DRNA
$19.3M 2.11%
1,223,925
-177,031
-13% -$2.41M
2018 Q3
3 quarters
PVLA icon
17
Palvella Therapeutics
PVLA
$2.13B
$18.6M 2.03%
49,428
-1,302
-3% -$388K
2016 Q2
12 quarters
FPRX
18
DELISTED
Five Prime Therapeutics
FPRX
$18.1M 1.98%
3,003,342
-61,004
-2% -$583K
2018 Q2
4 quarters
XENE icon
19
Xenon Pharmaceuticals
XENE
$3.69B
$17.2M 1.88%
1,741,600
-47,174
-3% -$451K
2014 Q4
18 quarters
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$822M
$16.4M 1.79%
1,764,784
-222,885
-11% -$1.62M
2017 Q4
6 quarters
IDYA icon
21
IDEAYA Biosciences
IDYA
$2.53B
$15M 1.64%
+1,505,429
New +$16.4M
2019 Q2
0 quarters
EOCN icon
22
Eocene
EOCN
$1.87M
$13.5M 1.47%
1,273
-32
-2% -$330K
2018 Q2
4 quarters
CCXI icon
23
DELISTED
ChemoCentryx
CCXI
$13.2M 1.44%
1,414,515
-50,000
-3% -$579K
2013 Q2
24 quarters
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.09B
$12.9M 1.41%
1,063,802
-59,453
-5% -$657K
2017 Q4
6 quarters
AKRO icon
25
DELISTED
Akero Therapeutics
AKRO
$12.4M 1.36%
+648,348
New +$12.3M
2019 Q2
0 quarters

Similar funds

BVF Inc's Q2 2019 Portfolio in Review

As of Q2 2019, BVF Inc held 61 positions worth $916M, up 2.5% from $893M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

BVF Inc's Q2 2019 filing shows 8 new, 22 increased, 19 reduced and 5 closed positions. Its largest new stake was IDEAYA Biosciences: 1,505,429 shares worth $15M. The largest sale was Array Biopharma, an estimated $62.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BVF Inc's largest Q2 2019 buy was IDEAYA Biosciences: 1,505,429 shares worth $15M.
  • BVF Inc added most to Calithera Biosciences in Q2 2019, an estimated $21.2M increase.
  • BVF Inc's biggest Q2 2019 reduction was Array Biopharma, cutting an estimated $62.5M.
  • BVF Inc fully exited argenx in Q2 2019, selling an estimated $10.1M.
  • BVF Inc's ten largest holdings make up 50% of its $916M portfolio in Q2 2019.
  • BVF Inc opened 8 new positions and closed 5 in Q2 2019.
  • BVF Inc's portfolio value rose 2.5% quarter-over-quarter to $916M.

Based on BVF Inc's 13F filing for Q2 2019, filed 14 Aug 2019.